(0.07%) 5 472.88 points
(0.09%) 39 145 points
(0.37%) 17 784 points
(0.00%) $80.83
(-3.66%) $2.66
(-0.76%) $2 313.00
(0.23%) $28.94
(3.64%) $1 022.30
(0.28%) $0.936
(0.69%) $10.68
(0.45%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs...
Stats | |
---|---|
今日成交量 | 65 279 |
平均成交量 | 304 979 |
市值 | 82.04M |
EPS | $-0.330 ( Q1 | 2024-05-13 ) |
下一个收益日期 | ( $-0.310 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.080 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00800 (0.47%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-07 | Formela Jean Francois | Buy | 17 520 | Stock Option (Right to Buy) |
2024-06-07 | Bonita David P | Buy | 17 520 | Stock Option (Right to Buy) |
2024-06-07 | Wooster Richard | Buy | 17 520 | Stock Option (Right to Buy) |
2024-06-07 | Dukes Iain D. | Buy | 17 520 | Stock Option (Right to Buy) |
2024-06-07 | Hughes Owen | Buy | 17 520 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
99.01 |
Last 95 transactions |
Buy: 6 136 538 | Sell: 817 436 |
音量 相关性
Ikena Oncology, Inc. 相关性 - 货币/商品
Ikena Oncology, Inc. 财务报表
Annual | 2023 |
营收: | $9.16M |
毛利润: | $8.14M (88.86 %) |
EPS: | $-1.630 |
FY | 2023 |
营收: | $9.16M |
毛利润: | $8.14M (88.86 %) |
EPS: | $-1.630 |
FY | 2022 |
营收: | $15.62M |
毛利润: | $13.58M (86.98 %) |
EPS: | $-1.840 |
FY | 2021 |
营收: | $30.99M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.951 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Ikena Oncology, Inc.
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。